Intervention Protocol

Cyclophosphamide for connective tissue disease–associated interstitial lung disease

  1. Ian N Glaspole1,*,
  2. Glen P Westall1,
  3. Nicole SL Goh1,
  4. Anne E Holland2,3,4

Editorial Group: Cochrane Airways Group

Published Online: 12 JAN 2014

DOI: 10.1002/14651858.CD010908

How to Cite

Glaspole IN, Westall GP, Goh NSL, Holland AE. Cyclophosphamide for connective tissue disease–associated interstitial lung disease (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010908. DOI: 10.1002/14651858.CD010908.

Author Information

  1. 1

    Alfred Hospital, Department of Allergy, Immunology and Respiratory Medicine, Melbourne, Victoria, Australia

  2. 2

    La Trobe University, School of Physiotherapy, Melbourne, Victoria, Australia

  3. 3

    Alfred Health, Department of Physiotherapy, Melbourne, Victoria, Australia

  4. 4

    Institute for Breathing and Sleep, Melbourne, Victoria, Australia

*Ian N Glaspole, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Commercial Road, Melbourne, Victoria, 3004, Australia. i.glaspole@alfred.org.au. glassher@bigpond.net.au.

Publication History

  1. Publication Status: New
  2. Published Online: 12 JAN 2014

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess the efficacy and adverse effects of cyclophosphamide in the treatment of CTD-ILD.